The Lancet Infectious Diseases CommissionSepsis: a roadmap for future research
Section snippets
Introduction: facing the challenge of sepsis
Patients with sepsis—a severe infection associated with organ dysfunction1—constitute a large proportion of the critically ill population and, although outcomes have improved,2 mortality remains higher than 25–30%, and even 40–50% when shock is present.3 No effective specific anti-sepsis treatments exist, therefore management of patients with sepsis relies mainly on early recognition allowing correct therapeutic measures to be started rapidly, including administration of appropriate
An unresolved issue
An important difference exists between a definition that is used to identify an individual who has a specific disorder and a definition that is used for epidemiological purposes. The former definition might have therapeutic, prognostic, or sociological implications for the patient and will need to be pragmatic and easy to apply. By contrast, an epidemiological definition will often be used for clinical trials or for public health surveillance reasons and will need to be as robust and rigorous
The global epidemiology of sepsis
Sepsis is both one of the best known yet most poorly understood medical disorders. First recognised by Hippocrates, sepsis can be described as the state in which a host mounts an inflammatory response to an invading pathogen with poor results. The lay definition states that sepsis is a life-threatening disorder that arises when the body's response to an infection injures its own tissues and organs. Sepsis leads to shock, multiple organ failure, and death, especially if not recognised early and
Diagnostic microbiology
Diagnostic microbiology stands at the epicentre of the tests for sepsis in patients. Nowadays, microbiological studies for the detection of bacteria or fungi in blood, body fluids, or relevant tissues continue to rely for the most part on conventional culture-based systems, which remain the gold standard. Blood cultures are positive in 30–40% of patients with severe sepsis and septic shock.123 In most instances bloodstream infections are intermittent and the circulating microbial loads are low,
Molecular targets and experimental therapies for sepsis
Conventional management principles with timely administration of intravenous fluids, oxygen, and antimicrobials combined with so-called source control, drainage of infectious foci, and advanced organ support in an intensive-care setting have reduced the overall mortality of severe sepsis to historically low rates (<20%).2, 7 Regrettably, long-term outcomes suggest that substantial residual morbidity and excess mortality risks persist for survivors after initial treatment for septic shock. The
Failure of clinical sepsis trials
As we have noted earlier, although the outcome of patients with sepsis has improved substantially in recent years,2, 51 this improvement in outcome has not been accomplished by any of the many adjuvant therapies tested in more than 100 phase 2 and phase 3 clinical sepsis trials.308, 309 Rather, the improved sepsis prognosis is probably mainly caused by an increased recognition and faster intervention by health-care services for cases of sepsis than was previously achieved, possibly due to
Sepsis: a call to action
In conceiving and writing this Commission, our intent has been two fold. The first was to describe the present status of what is one of those most challenging medical disorders in routine clinical practice, and the second, to identify those areas in which we think research is most crucial in driving forward transformational change. This second intent, what we have called the roadmap for the future, has informed this call to action (panel 2). We acknowledge that we have intentionally left
References (349)
- et al.
Sepsis definitions: time for change
Lancet
(2013) - et al.
Assessment of the worldwide burden of critical illness: the intensive care over nations (ICON) audit
Lancet Respir Med
(2014) - et al.
Sepsis: current dogma and new perspectives
Immunity
(2014) - et al.
Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells
J Biol Chem
(2006) - et al.
The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study
Lancet Respir Med
(2014) - et al.
American College of Chest Physicians/Society of Critical Care Medicine. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
Chest
(1992) - et al.
Critical care and the global burden of critical illness in adults
Lancet
(2010) - et al.
GBD 2010: a multi-investigator collaboration for global comparative descriptive epidemiology
Lancet
(2012) - et al.
Time-critical mortality conditions in low-income and middle-income countries. [letter]
Lancet
(2013) - et al.
The epidemiology of sepsis in patients with malignancy
Chest
(2006)
Tobacco smoking increases the risk for death from pneumococcal pneumonia
Chest
Exercise training prevents skeletal muscle damage in an experimental sepsis model
Clinics (Sao Paulo)
Rac1 mediates sex difference in cardiac tumor necrosis factor-alpha expression via NADPH oxidase-ERK1/2/p38 MAPK pathway in endotoxemia
J Mol Cell Cardiol
Estradiol receptors agonists induced effects in rat intestinal microcirculation during sepsis
Microvasc Res
Hemoglobin C associated with protection from severe malaria in the Dogon of Mali, a West African population with a low prevalence of hemoglobin S
Blood
The toll-like receptor 4 Asp299Gly variant: no influence on LPS responsiveness or susceptibility to pulmonary tuberculosis in The Gambia
Tuberculosis (Edinb)
Spread of an inactive form of caspase-12 in humans is due to recent positive selection
Am J Hum Genet
Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012
JAMA
Regulatory mandates for sepsis care—reasons for caution
N Engl J Med
Circulatory shock
N Engl J Med
Early goal-directed therapy in the treatment of severe sepsis and septic shock
N Engl J Med
A randomized trial of protocol-based care for early septic shock
N Engl J Med
Goal-directed resuscitation for patients with early septic shock
N Engl J Med
Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study
Am J Respir Crit Care Med
Intensive versus conventional glucose control in critically ill patients
N Engl J Med
Reduced cortisol metabolism during critical illness
N Engl J Med
Sepsis syndrome: a valid clinical entity
Crit Care Med
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
Crit Care Med
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
Crit Care Med
Systemic inflammatory response syndrome (SIRS): where did it come from and is it still relevant today?
Virulence
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012
Intensive Care Med
The search for effective therapy for sepsis: back to the drawing board?
JAMA
The immunopathogenesis of sepsis
Nature
Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting?
Crit Care Med
Choice of bacteria in animal models of sepsis
Infect Immun
Genomic responses in mouse models poorly mimic human inflammatory diseases
Proc Natl Acad Sci USA
A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis
Crit Care Med
The clinical research enterprise in critical care: what's right, what's wrong, and what's ahead?
Crit Care Med
Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock
Crit Care Med
Sepsis: time to reconsider the concept
Crit Care Med
Severe sepsis and septic shock
N Engl J Med
Role of selective V1a receptor agonism in ovine septic shock
Crit Care Med
Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial
Am J Respir Crit Care Med
Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock
Crit Care Med
Developing a clinically feasible personalized medicine approach to pediatric septic shock
Am J Respir Crit Care Med
Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study
Crit Care Med
A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation
Crit Care Med
The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C?
Crit Care Med
Outcome measures for clinical research in sepsis: a report of the 2nd Cambridge Colloquium of the International Sepsis Forum
Crit Care Med
“Merinoff symposium 2010: sepsis”-speaking with one voice
Mol Med
Cited by (779)
Host gene expression signatures to identify infection type and organ dysfunction in children evaluated for sepsis: a multicentre cohort study
2024, The Lancet Child and Adolescent HealthAdvancing sepsis clinical research: harnessing transcriptomics for an omics-based strategy - a comprehensive scoping review
2024, Informatics in Medicine UnlockedDexmedetomidine post-treatment exacerbates metabolic disturbances in septic cardiomyopathy via α<inf>2A</inf>-adrenoceptor
2024, Biomedicine and PharmacotherapyOptimizing artificial intelligence in sepsis management: Opportunities in the present and looking closely to the future
2024, Journal of Intensive MedicineTR4 worsen urosepsis by regulating GSDMD
2024, European Journal of Medical Research